The fungal cell wall and the mechanism of action of anidulafungin;La pared celular de los hongos y el mecanismo de acción de la anidulafungina

Revista Iberoamericana de Micologia

Volumn 25, Issue 2, 2008, Pages 78-82

  Pontón, José ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anidulafungin; Cell wall; Echinocandins; Fungi; Mechanism of action

Indexed keywords

ADHESIN; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CHITIN; ECHINOCANDIN; GLUCAN; GLYCOPROTEIN; MICAFUNGIN; RECEPTOR;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CELL WALL; CROSS RESISTANCE; DRUG MECHANISM; ENZYME INHIBITION; FUNGAL CELL; FUNGICIDAL ACTIVITY; IMMUNOGENICITY; NONHUMAN; OSMOTIC PRESSURE; REVIEW;

FUNGI;

ANTIFUNGAL AGENTS; CELL WALL; ECHINOCANDINS; FUNGI;

EID: 44849135496     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(08)70024-x     Document Type: Review

References (32)

1. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228-2230.
2. Beauvais A, Bruneau JM, Mol PC, Buitrago MJ, Legrand R, Latge JP. The glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2000; 83: 2273-2279.
3. Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. BioEssays 2006; 28: 799-808.
4. Brena S, Omaetxebarría MJ, Elguezabal N, Cabezas J, Moragues MD, Pontón J. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect Immun 2007; 75: 3680-3682.
5. Cutler JE. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 2005; 5: 383-392.
6. Chaffin WL, López-Ribot JL, Casanova M, Gozalbo D, Martínez JP. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol Mol Biol Rev 1998; 62: 130-180.
7. Chattaway FW, Holmes MR, Barlow JE. Cell wall composition of the mycelial and blastospore forms of Candida albicans. J Gen Microbiol 1968; 51: 367-376.
8. Douglas CM, Foor F, Marrinan JA, Morin N, Nielsen JB, Dahl AM, Mazur P, Baginsky W, Li W, el-Sherbeini M, Clemas JA, Mandala SM, Frommer BR, Kurtz MB. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of β-1,3-D-glucan synthase. Proc Natl Acad Sci USA 1994; 91: 12907-12911.
9. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-d-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471-2479.
10. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
11. Heitman J. Cell biology. A fungal Achilles' heel. Science 2005; 309: 2175-2176.
12. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-1878.
13. Kanetsuna F, Carbonell LM, Moreno RE, Rodriguez J. Cell wall composition of the yeast and mycelial forms of Paracoccidioides brasiliensis. J Bacteriol 1969; 97: 1036-1041.
14. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-2894.
15. Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-3251.
16. Lesage G, Shapiro J, Specht CA, Sdicu AM, Menard P, Hussein S, Tong AH, Boone C, Bussey H. An interactional network of genes involved in chitin synthesis in Saccharomyces cerevisiae. BMC Genet 2005; 6: 8.
17. Markovich S, Yekutiel A, Shalit I, Shadkchan Y, Osherov N. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48: 3871-3876.
18. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-2216.
19. Mazur P, Morin N, Baginsky W, El-Sherbeini M, Clemas JA, Nielsen JB, Foor F. Differential expression and function of two homologous subunits of yeast β1,3-D-glucan synthase. Mol Cell Biol 1995; 15: 5671-5681.
20. Mio T, Adachi-Shimizu M, Tachibana Y, Tabuchi H, Inoue SB, Yabe T, Yamada-Okabe T, Arisawa M, Watanabe T, Yamada-Okabe H. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol 1997; 179: 4096-4105.
21. Nimrichter L, Rodrigues ML, Rodrigues EG, Travassos LR. The multitude of targets for the immune system and drug therapy in the fungal cell wall. Microbes Infect 2005; 7: 789-798.
22. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273.
23. Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic potential of detection of (1-3)-β-D-glucan and antibodies to Candida albicans germ tubes for diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006; 23: 209-215.
24. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-130.
25. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-255.
26. Pontón J, Omaetxebarria MJ, Elguezabal N, Alvarez M, Moragues MD. Immunoreactivity of the fungal cell wall. Med Mycol 2001; 39 (Supl. 1): 101-110.
27. Pontón J, Quindós G. Mecanismos de resistencia a la terapéutica antifúngica. Med Clin (Barc) 2006; 126 (Supl. 1): 56-60.
28. Qadota H, Python CP, Inoue SB, Arisawa M, Anraku Y, Zheng Y, Watanabe T, Levin DE, Ohya Y. Identification of yeast Rho1p GTPase as a regulatory subunit of 61,3-glucan synthase. Science 1996; 272: 279-281.
29. Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K, The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell 2003; 2: 1200-1210.
30. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 1-23.
31. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005; 48: 246-250.
32. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Berti F, Norelli F, Galli C, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597-606.